OCULO THERAPY LLC
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.1Mattributed |
|---|---|
| Latest round | grant, $2.1M, 2024-01-01attributed |
| Founded | unknown |
| Headquarters | MEMPHIS, Tennessee |
| Industry | bio |
| Stage | unknown |
| Website | tavobio.com |
Tavo Biotherapeutics develops therapies for ophthalmic neurodegeneration, with a focus on glaucoma and retinal diseases. It targets patients losing vision to glaucoma and the ophthalmologists treating them. Programs aim at neuroprotective and disease-modifying mechanisms in eye care.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-01-01 | grant | $2.1M | undisclosed |
Detected tech stack
Google Analytics, Google Tag Manager, Framer Sites, MongoDB, Node.js, React 16.13.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.1M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $2.1M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | tavobio.com, read 2026-05-08 |
| Description | self-reported | tavobio.com, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.